Derivatives of piperazines as potential therapeutic agents for Alzheimer’s disease

Elena Popugaeva, Daria Chernyuk, Hua Zhang, Tatyana Y. Postnikova, Karina Pats, Elena Fedorova, Vladimir Poroikov, Aleksey V. Zaitsev, Ilya Bezprozvanny

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder that is the major cause of dementia in the elderly. There is no cure against AD. We have recently discovered a novel transient receptor potential canonical 6 (TRPC6)–mediated intracellular signaling pathway that regulates the stability of dendritic spines and plays a role in memory formation. We have previously shown that TRPC6 agonists exert beneficial effects in models of AD and may serve as lead compounds for development of AD therapeutic agents. In the current study, we used the Clarivate Analytics Integrity database to search for additional TRPC6 agonists. We selected four compounds to study as potential neuroprotective agents. We applied bioinformatics analyses to test the basic pharmacological properties of the selected compounds. We performed in vitro screening of these compounds to validate their ability to protect mushroom spines from amyloid toxicity and determined that two of these compounds exert neuroprotective effects in the nanomolar concentration range. We have chosen one of these compounds [piperazine (PPZ)] for further testing. In agreement with previously published data, we have shown that PPZ potentiates TRPC6 channels. We demonstrated that the neuroprotective mechanism of the investigated PPZ is based on activation of neuronal store-operated calcium entry in spines. We have shown that PPZ restores long-term potentiation induction in 6-month-old 5xFAD mouse hippocampal slices. The obtained results suggest that PPZ and its derivatives are potential lead molecules for development of AD therapeutic agents.

Original languageEnglish (US)
Pages (from-to)337-348
Number of pages12
JournalMolecular Pharmacology
DOIs
StatePublished - Apr 1 2019

Fingerprint

Piperazines
Alzheimer Disease
Neuroprotective Agents
Spine
Therapeutics
Dendritic Spines
Aptitude
Long-Term Potentiation
Agaricales
Computational Biology
Amyloid
Neurodegenerative Diseases
Dementia
piperazine
Databases
Pharmacology
Calcium

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Derivatives of piperazines as potential therapeutic agents for Alzheimer’s disease. / Popugaeva, Elena; Chernyuk, Daria; Zhang, Hua; Postnikova, Tatyana Y.; Pats, Karina; Fedorova, Elena; Poroikov, Vladimir; Zaitsev, Aleksey V.; Bezprozvanny, Ilya.

In: Molecular Pharmacology, 01.04.2019, p. 337-348.

Research output: Contribution to journalArticle

Popugaeva, E, Chernyuk, D, Zhang, H, Postnikova, TY, Pats, K, Fedorova, E, Poroikov, V, Zaitsev, AV & Bezprozvanny, I 2019, 'Derivatives of piperazines as potential therapeutic agents for Alzheimer’s disease', Molecular Pharmacology, pp. 337-348. https://doi.org/10.1124/mol.118.114348
Popugaeva, Elena ; Chernyuk, Daria ; Zhang, Hua ; Postnikova, Tatyana Y. ; Pats, Karina ; Fedorova, Elena ; Poroikov, Vladimir ; Zaitsev, Aleksey V. ; Bezprozvanny, Ilya. / Derivatives of piperazines as potential therapeutic agents for Alzheimer’s disease. In: Molecular Pharmacology. 2019 ; pp. 337-348.
@article{734a06d0a06343ba9d84b01b67ae6fea,
title = "Derivatives of piperazines as potential therapeutic agents for Alzheimer’s disease",
abstract = "Alzheimer’s disease (AD) is a neurodegenerative disorder that is the major cause of dementia in the elderly. There is no cure against AD. We have recently discovered a novel transient receptor potential canonical 6 (TRPC6)–mediated intracellular signaling pathway that regulates the stability of dendritic spines and plays a role in memory formation. We have previously shown that TRPC6 agonists exert beneficial effects in models of AD and may serve as lead compounds for development of AD therapeutic agents. In the current study, we used the Clarivate Analytics Integrity database to search for additional TRPC6 agonists. We selected four compounds to study as potential neuroprotective agents. We applied bioinformatics analyses to test the basic pharmacological properties of the selected compounds. We performed in vitro screening of these compounds to validate their ability to protect mushroom spines from amyloid toxicity and determined that two of these compounds exert neuroprotective effects in the nanomolar concentration range. We have chosen one of these compounds [piperazine (PPZ)] for further testing. In agreement with previously published data, we have shown that PPZ potentiates TRPC6 channels. We demonstrated that the neuroprotective mechanism of the investigated PPZ is based on activation of neuronal store-operated calcium entry in spines. We have shown that PPZ restores long-term potentiation induction in 6-month-old 5xFAD mouse hippocampal slices. The obtained results suggest that PPZ and its derivatives are potential lead molecules for development of AD therapeutic agents.",
author = "Elena Popugaeva and Daria Chernyuk and Hua Zhang and Postnikova, {Tatyana Y.} and Karina Pats and Elena Fedorova and Vladimir Poroikov and Zaitsev, {Aleksey V.} and Ilya Bezprozvanny",
year = "2019",
month = "4",
day = "1",
doi = "10.1124/mol.118.114348",
language = "English (US)",
pages = "337--348",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",

}

TY - JOUR

T1 - Derivatives of piperazines as potential therapeutic agents for Alzheimer’s disease

AU - Popugaeva, Elena

AU - Chernyuk, Daria

AU - Zhang, Hua

AU - Postnikova, Tatyana Y.

AU - Pats, Karina

AU - Fedorova, Elena

AU - Poroikov, Vladimir

AU - Zaitsev, Aleksey V.

AU - Bezprozvanny, Ilya

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Alzheimer’s disease (AD) is a neurodegenerative disorder that is the major cause of dementia in the elderly. There is no cure against AD. We have recently discovered a novel transient receptor potential canonical 6 (TRPC6)–mediated intracellular signaling pathway that regulates the stability of dendritic spines and plays a role in memory formation. We have previously shown that TRPC6 agonists exert beneficial effects in models of AD and may serve as lead compounds for development of AD therapeutic agents. In the current study, we used the Clarivate Analytics Integrity database to search for additional TRPC6 agonists. We selected four compounds to study as potential neuroprotective agents. We applied bioinformatics analyses to test the basic pharmacological properties of the selected compounds. We performed in vitro screening of these compounds to validate their ability to protect mushroom spines from amyloid toxicity and determined that two of these compounds exert neuroprotective effects in the nanomolar concentration range. We have chosen one of these compounds [piperazine (PPZ)] for further testing. In agreement with previously published data, we have shown that PPZ potentiates TRPC6 channels. We demonstrated that the neuroprotective mechanism of the investigated PPZ is based on activation of neuronal store-operated calcium entry in spines. We have shown that PPZ restores long-term potentiation induction in 6-month-old 5xFAD mouse hippocampal slices. The obtained results suggest that PPZ and its derivatives are potential lead molecules for development of AD therapeutic agents.

AB - Alzheimer’s disease (AD) is a neurodegenerative disorder that is the major cause of dementia in the elderly. There is no cure against AD. We have recently discovered a novel transient receptor potential canonical 6 (TRPC6)–mediated intracellular signaling pathway that regulates the stability of dendritic spines and plays a role in memory formation. We have previously shown that TRPC6 agonists exert beneficial effects in models of AD and may serve as lead compounds for development of AD therapeutic agents. In the current study, we used the Clarivate Analytics Integrity database to search for additional TRPC6 agonists. We selected four compounds to study as potential neuroprotective agents. We applied bioinformatics analyses to test the basic pharmacological properties of the selected compounds. We performed in vitro screening of these compounds to validate their ability to protect mushroom spines from amyloid toxicity and determined that two of these compounds exert neuroprotective effects in the nanomolar concentration range. We have chosen one of these compounds [piperazine (PPZ)] for further testing. In agreement with previously published data, we have shown that PPZ potentiates TRPC6 channels. We demonstrated that the neuroprotective mechanism of the investigated PPZ is based on activation of neuronal store-operated calcium entry in spines. We have shown that PPZ restores long-term potentiation induction in 6-month-old 5xFAD mouse hippocampal slices. The obtained results suggest that PPZ and its derivatives are potential lead molecules for development of AD therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=85065295006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065295006&partnerID=8YFLogxK

U2 - 10.1124/mol.118.114348

DO - 10.1124/mol.118.114348

M3 - Article

C2 - 30696719

AN - SCOPUS:85065295006

SP - 337

EP - 348

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

ER -